Solid tumours represent the next major frontier for bispecific antibody therapeutics, with significant unmet medical need and opportunities to expand efficacy beyond hematologic malignancies. This workshop will explore strategies to overcome the unique challenges of solid tumours, including physical barriers, heterogeneous target expression, and an immunosuppressive tumour microenvironment. Participants will learn to optimise tumour penetration, enhance immune engagement, and leverage preclinical models to anticipate clinical outcomes and accelerate the path from discovery to clinic.

This workshop will gather experts to discuss:

• Understand key barriers to efficacy and learn how physical and immunological features of solid tumours impact bispecific performance
• Enhance tumour penetration and activity by applying cutting-edge engineering strategies and combination approaches to maximise therapeutic impact
• Leverage hematologic learnings for solid tumours and translate proven principles from blood cancer bispecifics to inform solid tumour design
• Predict clinical success with preclinical tools by evaluating models and predictive strategies to anticipate efficacy, optimise dosing, and reduce translational risk